Phase I trial of Vigil® personalized engineered autologous tumor cells (EATC) in ovarian cancer
| Autor: | Rocconi, R.P., Scalici, J.M., Barve, M., Manning, L., Wallraven, G., Senzer, N., Nemunaitis, J. |
|---|---|
| Zdroj: | In Gynecologic Oncology June 2018 149 Supplement 1:40-41 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect